BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation

Mei-Chun Yeh,1 Ben J Wu,1 Yue Li,1 Mina Elahy,1 Leonel Prado-Lourenco,1 Jim Sockler,2 Herman Lau,3 Ric O Day,4 Levon M Khachigian1 1Vascular Biology and Translational Research, School of Medical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, 2052, Australia; 2S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yeh MC, Wu BJ, Li Y, Elahy M, Prado-Lourenco L, Sockler J, Lau H, Day RO, Khachigian LM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	inflammation pathology bone erosion rheumatoid arthritis dibenzoxazepinone Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/46416595016a4536b75cbdc3210ca9fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:46416595016a4536b75cbdc3210ca9fc
record_format	dspace
spelling	oai:doaj.org-article:46416595016a4536b75cbdc3210ca9fc2021-12-02T16:32:01ZBT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation1178-7031https://doaj.org/article/46416595016a4536b75cbdc3210ca9fc2021-03-01T00:00:00Zhttps://www.dovepress.com/bt2-suppresses-human-monocytic-endothelial-cell-adhesion-bone-erosion--peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Mei-Chun Yeh,1 Ben J Wu,1 Yue Li,1 Mina Elahy,1 Leonel Prado-Lourenco,1 Jim Sockler,2 Herman Lau,3 Ric O Day,4 Levon M Khachigian1 1Vascular Biology and Translational Research, School of Medical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, 2052, Australia; 2Statistical Operations & Programming, Datapharm Australia Pty Ltd, Drummoyne, NSW, 2047, Australia; 3BJC Health, Chatswood, NSW, 2067, Australia; 4Department of Clinical Pharmacology & Toxicology, Therapeutics Centre, St Vincent’s Hospital, UNSW Medicine and Health, Darlinghurst, NSW, 2010, AustraliaCorrespondence: Levon M KhachigianVascular Biology and Translational Research, School of Medical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, 2052, AustraliaTel +61 2 9385 2537Email L.Khachigian@unsw.edu.auIntroduction: Inflammation and bone erosion are processes key to the pathogenesis of rheumatoid arthritis, a systemic autoimmune disease causing progressive disability and pain, impacting around 1.3 million people in the United States alone. However, many patients do not respond sufficiently to existing therapies or benefit is not sustained and alternate therapeutic approaches are lacking. We recently identified the dibenzoxazepinone BT2, which inhibits ERK phosphorylation, from a high-throughput chemical screen and identified its ability to inhibit angiogenesis and vascular leakiness.Methods: Here we evaluated BT2 for potential anti-inflammatory activity in in vitro models of human monocytic-endothelial cell adhesion, monocytic cell extravasation and collagen antibody-induced arthritis in mice.Results: BT2 inhibits human monocytic cell adhesion to IL-1ß-treated human endothelial cells and inhibits monocytic transendothelial migration toward MCP-1. In mice rendered arthritic, single systemic administration of BT2 prevented footpad swelling, bone destruction and TRAP+ cells in the joints. BT2 suppressed inducible circulating levels of IL-1ß, IL-2 and IL-6 to normal levels without affecting levels of IL-4 or IL-10 among other cytokines. BT2 also inhibited the expression of pro-inflammatory adhesion molecules ICAM-1 and VCAM-1 in arthritic joints. There was no evidence of toxicity following intraperitoneal, gavage or intraarticular administration of BT2.Conclusion: BT2 is a novel small molecule inhibitor of joint inflammation, bone erosion, pro-inflammatory cytokine and adhesion molecule expression. This suggests the potential clinical utility of BT2 as a new anti-inflammatory agent.Keywords: inflammation, pathology, bone erosion, rheumatoid arthritis, dibenzoxazepinoneYeh MCWu BJLi YElahy MPrado-Lourenco LSockler JLau HDay ROKhachigian LMDove Medical Pressarticleinflammationpathologybone erosionrheumatoid arthritisdibenzoxazepinonePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 1019-1028 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	inflammation pathology bone erosion rheumatoid arthritis dibenzoxazepinone Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	inflammation pathology bone erosion rheumatoid arthritis dibenzoxazepinone Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Yeh MC Wu BJ Li Y Elahy M Prado-Lourenco L Sockler J Lau H Day RO Khachigian LM BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation
description	Mei-Chun Yeh,1 Ben J Wu,1 Yue Li,1 Mina Elahy,1 Leonel Prado-Lourenco,1 Jim Sockler,2 Herman Lau,3 Ric O Day,4 Levon M Khachigian1 1Vascular Biology and Translational Research, School of Medical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, 2052, Australia; 2Statistical Operations & Programming, Datapharm Australia Pty Ltd, Drummoyne, NSW, 2047, Australia; 3BJC Health, Chatswood, NSW, 2067, Australia; 4Department of Clinical Pharmacology & Toxicology, Therapeutics Centre, St Vincent’s Hospital, UNSW Medicine and Health, Darlinghurst, NSW, 2010, AustraliaCorrespondence: Levon M KhachigianVascular Biology and Translational Research, School of Medical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, 2052, AustraliaTel +61 2 9385 2537Email L.Khachigian@unsw.edu.auIntroduction: Inflammation and bone erosion are processes key to the pathogenesis of rheumatoid arthritis, a systemic autoimmune disease causing progressive disability and pain, impacting around 1.3 million people in the United States alone. However, many patients do not respond sufficiently to existing therapies or benefit is not sustained and alternate therapeutic approaches are lacking. We recently identified the dibenzoxazepinone BT2, which inhibits ERK phosphorylation, from a high-throughput chemical screen and identified its ability to inhibit angiogenesis and vascular leakiness.Methods: Here we evaluated BT2 for potential anti-inflammatory activity in in vitro models of human monocytic-endothelial cell adhesion, monocytic cell extravasation and collagen antibody-induced arthritis in mice.Results: BT2 inhibits human monocytic cell adhesion to IL-1ß-treated human endothelial cells and inhibits monocytic transendothelial migration toward MCP-1. In mice rendered arthritic, single systemic administration of BT2 prevented footpad swelling, bone destruction and TRAP+ cells in the joints. BT2 suppressed inducible circulating levels of IL-1ß, IL-2 and IL-6 to normal levels without affecting levels of IL-4 or IL-10 among other cytokines. BT2 also inhibited the expression of pro-inflammatory adhesion molecules ICAM-1 and VCAM-1 in arthritic joints. There was no evidence of toxicity following intraperitoneal, gavage or intraarticular administration of BT2.Conclusion: BT2 is a novel small molecule inhibitor of joint inflammation, bone erosion, pro-inflammatory cytokine and adhesion molecule expression. This suggests the potential clinical utility of BT2 as a new anti-inflammatory agent.Keywords: inflammation, pathology, bone erosion, rheumatoid arthritis, dibenzoxazepinone
format	article
author	Yeh MC Wu BJ Li Y Elahy M Prado-Lourenco L Sockler J Lau H Day RO Khachigian LM
author_facet	Yeh MC Wu BJ Li Y Elahy M Prado-Lourenco L Sockler J Lau H Day RO Khachigian LM
author_sort	Yeh MC
title	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation
title_short	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation
title_full	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation
title_fullStr	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation
title_full_unstemmed	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation
title_sort	bt2 suppresses human monocytic-endothelial cell adhesion, bone erosion and inflammation
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/46416595016a4536b75cbdc3210ca9fc
work_keys_str_mv	AT yehmc bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT wubj bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT liy bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT elahym bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT pradolourencol bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT socklerj bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT lauh bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT dayro bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation AT khachigianlm bt2suppresseshumanmonocyticendothelialcelladhesionboneerosionandinflammation
_version_	1718383805578870784

BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation

Ejemplares similares